Findings
========

Amyotrophic Lateral Sclerosis (ALS) is a progressive lethal disorder of motor neurons of the spinal cord and brain. More than 90% of ALS patients are sporadic (SALS), not showing any familial trait. Approximately 10% of cases are familial (FALS), and within these lie several distinct forms of the disease. The most common form of FALS is autosomal dominant for which to date 2 genes have been identified: ALS1, with adult-onset caused by mutations in the gene encoding the cytosolic antioxidant enzyme Cu, Zn-superoxide dismutase (*Sod1*) \[[@B1],[@B2]\]; and ALS4, a rare juvenile-onset disorder, associated with mutations of the senataxin gene (*SETX*) \[[@B3]\]. An autosomal recessive, juvenile-onset form (ALS2), has been associated with mutations of the *Alsin*gene located at 2q33 \[[@B4]\]. To date over 100 different missense mutations in the *Sod1*gene \[[@B5]\] and up to eight described mutations in the *Alsin*gene have been reported \[[@B6]\].

By contrast, sporadic ALS is believed to be a multi-factorial disease in which modifying genes and environmental agents affect its clinical manifestation, but few associated genes have so far been identified \[[@B7]-[@B13]\]. De novo mutations in the *Sod1*gene have only occasionally been observed in sporadic cases of ALS suggesting that mutations in this gene are a rare cause of non familial forms of ALS \[[@B14],[@B15]\].

The finding by [Nishimura et al.]{.ul}\[[@B16]\] of a missense mutation in the VAMP/synaptobrevin-associated membrane protein B (*VAPB*) gene in autosomal dominant motoneuron diseases (ALS8), prompted us to investigate the entire coding region of this gene in 125 SALS patients.

Following informed consent, blood was taken from 125 unrelated Caucasian patients from Southern Italy, who fulfilled the El Escorial criteria \[[@B17]\] for ALS. Samples were also taken from 150 controls, matched for age, sex and geographic region. Clinical information is provided in Table [1](#T1){ref-type="table"}. Lymphocyte DNA was extracted from blood samples using standard procedure. *Sod1*mutation-negative patients were screened using primer flanking the intron-exon regions of the *VAPB*gene. The PCR products were analyzed by Denaturing High Performance Liquid Chromatography (DHPLC) on a WAVE Nucleic Acid Fragment Analysis System (Transgenomic Inc., Mountain View, CA). Representative samples with abnormal profile in DHPLC were sequenced by the ABI Prism BigDye Terminator cycle sequencing ready reaction kit (Perkin Elmer- Applied Biosystems Inc., Foster City, CA).

DHPLC analysis of the *VAPB*gene \[GenBank accession no. [AL035455](AL035455)\] detected five variant profiles in 83 out of 125 SALS patients. Direct sequencing of PCR products revealed 3 nucleotide substitutions. Two nucleotide substitutions, g.134585C\>T and g.134688A\>G were found within intron 3 of the gene, harbouring 4 variant DHPLC profiles, because of their combination in homozygous or heterozygous states. These polymorphisms were already present in the SNP database as rs 2234487 and rs 2234488, respectively \[[@B18]\]. The frequencies in our SALS patients and in control population were 65% vs 64% for the rs 2234487 and 42% vs 45% for the rs 2234488, respectively.

The third nucleotide substitution was the only substitution present in the coding region of the *VAPB*gene and it occurred within exon 4 at nucleotide g.138864T\>G (Asp130Glu).

The Asp130Glu variation is located between MSP and Coiled-coil domains, and involves an aminoacid residue of aspartic acid not conserved among different species. We identified this variation in heterozygous state in three out of 125 SALS patients (2.0%) and in three of 150 (2.4%) sex-age-matched healthy subjects from the same geographical area, suggesting that this aminoacidic substitution is not causative of the disease.

The data presented herein suggest that *VAPB*mutations are not a common cause of adult-onset SALS in Italian population. Further, the novel nucleotide variation identified in exon 4 of *VAPB*gene represents a polymorphism, probably linked to a restrict geographic area.
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###### 

Clinical information of the studied populations

  **Subject**   **Total**   **Male/Female**   **Age at Onset^a^(years)**   **Mean Age**             **Spinal Onset**   **Bulbar Onset**
  ------------- ----------- ----------------- ---------------------------- ------------------------ ------------------ ------------------
  SALS^b^       125         66/59             54.9 (40--80)                58.9 (41--88, SD 10.5)   106                19
  Controls      150         69/81             \-                           59.9 (40--78, SD 12.2)   \-                 \-

^a^Mean age of onset (with lowest/highest and Standard Deviation values in parentheses);

^b^SALS: Sporadic Amyotrophic Lateral Sclerosis
